CPF Texas’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

CPF Texas’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$1.15M	Hold	12,000	–	–	0.55%	56
2018 Q2	$1.14M	Hold	12,000	–	–	0.61%	49
2018 Q1	$1.05M	Hold	12,000	–	–	0.54%	53
2017 Q4	$1.02M	Buy	+12,000	New	+$1.01M	0.5%	52

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

CPF Texas's XBI Position: Q3 2018 in Review

CPF Texas held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2018 at 12,000 shares worth $1.15M. The position accounts for 0.55% of the portfolio, ranked #56.

CPF Texas first reported a position in XBI in Q4 2017 and has held it in 4 quarters since. 432 funds tracked by Wall St. Rank hold XBI as of Q3 2018.

CPF Texas held 12,000 shares of State Street SPDR S&P Biotech ETF worth $1.15M as of Q3 2018.
CPF Texas left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2018.
State Street SPDR S&P Biotech ETF made up 0.55% of CPF Texas's portfolio in Q3 2018, its #56 holding.
CPF Texas first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 4 quarters since.
432 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2018.

Based on CPF Texas's 13F filing for Q3 2018, filed 14 Nov 2018.